During the last 20 years, several human in vivo studies have shown a good diagnostic performance of cerebrospinal fluid (CSF) BACE1 activity/levels in discriminating AD patients from mild cognitive impairment (MCI) subjects and healthy controls [21,22,23,24,25,26]. The gene discussed is BACE1; the disease is Alzheimer disease.